PubMed Health⌕ Search

Biomedical subjects

S Carter

Publications and source records attributed to S Carter.

At least 145 records · Page 8Linked to original sources
PubMed1977

Biochemical markers in bronchial carcinoma.

A total of 107 patients with bronchial carcinoma have been studied for the presence of potential circulating tumour markers which might be used as indicators of recurrence after primary treatment. Plasma carcinoembryonic antigen (CEA) levels were estimated in every patient and, after a preliminary hormone screening study, plasma calcitonin (CT) and parathyroid hormone (PTH) levels were assayed in 66 patients. Oat-cell tumours proved to be of particular interest in that CEA levels greater than 40 microgram/l were measured (initially or subsequently) in 40.6 percent and CT levels were elevated in 75 percent. Longitudinal studies point towards the possible use of elevated marker levels as guides to therapy when all other features of recurrent disease are lacking. It is clear that no ideal tumour marker exists for bronchial carcinoma but in an individual case an abnormal level of one or more marker substances may provide a valuable aid to treatment.

Bronchial Neoplasms↗
PubMed1977

The clinical diagnostic value of the carcinoembryonic antigen (CEA) in haematuria.

Plasma and urinary CEA levels in patients presenting with haematuria have been studied to assess whether they facilitate the differentiation between benign and malignant urothelial conditions. Plasma CEA is of no diagnostic value although, if raised, it may suggest an invasive tumour. Urinary CEA levels are only of value in the absence of urinary infection; even then, only 37% of the cases with overt urothelial tumours had raised titres. A knowledge of the urinary CEA level, therefore, would seem to contribute little to the diagnosis of patients presenting with haematuria and all patients must still be investigated by the conventional techniques of urinary bacteriology, cytology, intravenous pyelography and cystourethroscopy.

Carcinoembryonic Antigen↗
PubMed1977

Diagnostic usefulness of plasma carcinoembryonic antigen levels in acute and chronic liver disease.

Raised plasma carcinoembryonic antigen (CEA) levels were found in over 90% of 71 patients with chronic liver disease and 50% of 16 patients with acute liver damage. Levels increasing chronicity and clinical severity of disease. In individual patients, the plasma CEA level fluctuated with the clinical condition. Persistently normal levels were never found in patients with chronic liver disease in poor clinical condition. A very high level suggests a bad prognosis. If CEA is considered together with SGPT, a discriminant function can be calculated, separating patients with acute liver damage and those with an acute exacerbation of chronic active hepatitis, with a high degree of certainty. In acute damage, peak CEA levels occur later than the time of maximum liver necrosis, suggesting that the rise is not owing to release of CEA from damaged cells. There is no significant difference in CEA level between patients with and without spontaneous or surgical portosystemic shunts, suggesting that high levels are not attributable to bypass of the liver. The timing of the rise in CEA in acute liver damage suggests that raised levels may be associated with regeneration. The tendency for higher levels to occur in those patients with greater disturbances of liver function suggests altered metabolism or excretion of CEA.

Acute Disease↗
PubMed1974

Role of serial plasma C.E.A. assays in detection of recurrent and metastatic colorectal carcinomas.

Serial estimations of plasma carcinoembryonic antigen (C.E.A.) levels have been carried out in 220 patients with colorectal carcinomas who had potentially and apparently curative surgery. In a two-year follow-up period 53 patients developed recurrences or metastases. In 36 of these patients sustained rises in plasma C.E.A. titres occurred synchronously with or between three and 18 months before the clinical detection of recurrences or metastases. The use of serial plasma C.E.A. assays is therefore recommended as an additional diagnostic aid for the earlier detection of recurrent or metastatic colorectal carcinomas.

Bone Neoplasms↗